[1] 郭小贝，田欣伦. 囊性纤维化// 中国第一批罕见病目录释 义［M］.北京: 人民卫生出版社，2018:315-317.
[2]Soret P, Vandenborght L E, Francis F, et al. Respiratory mycobiome and suggestion of inter-kingdom network during acute pulmonary exacerbation in cystic fibrosis[J].
Scientific reports, 2020, 10(1): 3589.
[3] Xu J, Yin Y, Zhang L, et al. Four case reports of Chinese cystic fibrosis patients and literature review[J]. Pediatric Pulmonology, 2017, 52(8): 1020-1028.
[4] Stick SM, Foti A, Ware RS, Tiddens H, Clements BS, Armstrong DS, et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT
CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respir Med. 2022;10(8):776-84.
[5] Akkerman-Nijland A M, Möhlmann J E, Akkerman O W, et al. The long-term safety of chronic azithromycin use in adult patients with cystic fibrosis, evaluating
biomarkers for renal function, hepatic function and electrical properties of the heart[J]. Expert Opinion on Drug Safety, 2021, 20(8): 959-963.
[6]中华医学会心血管病学分会心律失常学组,中华心血管病杂志编辑委员会,中国心脏起搏与心电生理杂志编辑委员会. 获得性长 QT 间期综合征的防治建议[ J]. 中华心血管病杂
志,2010,38(11):961-969.
[7] Proesmans M, Balinska ‐Miskiewicz W, Dupont L, et al. Evaluating the “Leeds criteria” for Pseudomonas aeruginosa infection in a cystic fibrosis centre[J]. Eur Respir J,
2006, 27(5): 937 ‐943.
[8]Ratjen F, Moeller A, Mckinney ML, et al. Eradication of early P. Aeruginosa infection in children<7years of age with cystic fibrosis: the early study [J]. J Cyst Fibros,
2019, 18(1): 78 ‐85.
[9]囊性纤维化诊断与治疗中国专家共识编写组,中国罕见病联盟呼吸病学分会,中国支气管扩张症临床诊治与研究联盟. 囊性纤维化诊断与治疗中国专家共识（2023版）[J]. 中华结
核和呼吸杂志,2023,46(4):352-372.
[10]Schwarz C，Sutharsan S，Epaud R，et al.Tezacaftor ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events［J］.J
Cyst Fibros，2021，20（2）:228-233.
[11] Middleton PG，Mall MA，Drevinek P，et al. Elexacaftortezacaftor-ivacaftor for cystic fibrosis with a single Phe508del Allele［J］.New England J of Med，2019，381（19）:
1809-1819.
[12]Burgel P R, Munck A, Durieu I, et al. Real-life safety and effectiveness of lumacaftor–ivacaftor in patients with cystic fibrosis[J]. American Journal of Respiratory and
Critical Care Medicine, 2020, 201(2): 188-197.